Comprehensive Psychotropic Renal Dosing, Adverse Drug Reactions, and Neuropsychiatric Emergencies

0.0(0)
Studied by 0 people
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/61

flashcard set

Earn XP

Description and Tags

Comprehensive vocabulary flashcards covering psychotropic renal dosing rules, class-specific adverse drug reactions, boxed warnings, and emergency neuropsychiatric syndromes verified against FDA labeling.

62 Terms

1
New cards

Cockcroft-Gault formula

The standard mathematical formula used to estimate creatinine clearance: CrCl (mL/min)=[(140−age in years)×weight in kg]72×serum creatinine in mg/dL\text{CrCl (mL/min)} = \frac{[(140 - \text{age in years}) \times \text{weight in kg}]}{72 \times \text{serum creatinine in mg/dL}}, multiplied by 0.850.85 for women, using actual or adjusted body weight when BMI deviates significantly from normal.

2
New cards

Creatinine clearance bands

Renal staging categories for medication dosing: ≥90 mL/min\ge 90\,\text{mL/min} indicates normal clearance (standard dosing); 60–89 mL/min60\text{--}89\,\text{mL/min} indicates mild impairment (most drugs unchanged); 30–59 mL/min30\text{--}59\,\text{mL/min} indicates moderate impairment (adjustments begin for many drugs); and <30 mL/min< 30\,\text{mL/min} indicates severe impairment (adjust or avoid several agents).

3
New cards

Renally cleared psychotropics

Psychotropic medications that depend on kidney excretion and require dosing modifications or vigilance in renal impairment, including lithium, gabapentin, pregabalin, memantine, galantamine, paliperidone, duloxetine, venlafaxine, desvenlafaxine, brexpiprazole, risperidone, buspirone, mirtazapine, and bupropion.

4
New cards

Non-renally adjusted psychotropics

Common psychotropic agents requiring no standard renal dose adjustments: sertraline, escitalopram, citalopram, fluoxetine, vortioxetine, donepezil, rivastigmine, aripiprazole, olanzapine, quetiapine, and haloperidol (vigilance still required in frail older adults).

5
New cards

Lithium renal management rule

A narrow therapeutic index mood stabilizer that is entirely renally cleared; any change in renal function, dehydration, NSAIDs, ACE inhibitors/ARBs, or thiazides alters blood levels, requiring levels to be checked 5–75\text{--}7 days after dosage changes and immediate holding during acute kidney injury or dehydrating illness.

6
New cards

Duloxetine renal threshold

An SNRI prescribing rule mandating avoidance if GFR is <30 mL/min< 30\,\text{mL/min}.

7
New cards

Venlafaxine renal adjustment

Extended-release SNRI dosing recommendation capping the dose at a maximum of 112.5 mg112.5\,\text{mg} once daily in the presence of renal impairment.

8
New cards

Desvenlafaxine renal dosing

An SNRI dosing protocol requiring a maximum of 50 mg/day50\,\text{mg/day} for CrCl 30–89 mL/min\text{CrCl } 30\text{--}89\,\text{mL/min}, and 50 mg50\,\text{mg} every other day in severe renal impairment or end-stage renal disease (ESRD).

9
New cards

Mirtazapine renal rule

A tetracyclic antidepressant whose clearance decreases in renal impairment, requiring cautious administration and slower titration.

10
New cards

Bupropion renal adjustment

An antidepressant guideline recommending a reduction in dose, frequency of dosing, or both in the presence of renal impairment.

11
New cards

Paroxetine renal adjustment

An SSRI dosing directive to restrict therapy to the lower end of the dosing range in cases of severe renal impairment.

12
New cards

Buspirone renal rule

An anxiolytic guideline directing dose reduction and cautious use due to an approximate 44-fold increase in drug area under the curve (AUC) during renal impairment.

13
New cards

Gabapentin renal dosing

A completely renally cleared anticonvulsant and analgesic requiring dosing via CrCl-based protocols (e.g., 300–600 mg300\text{--}600\,\text{mg} three times daily for CrCl≥60 mL/min\text{CrCl} \ge 60\,\text{mL/min}; halving the daily dose and extending the dosing interval for CrCl<30 mL/min\text{CrCl} < 30\,\text{mL/min}).

14
New cards

Paliperidone renal thresholds

An SGA renal guideline establishing an initial dose of 3 mg3\,\text{mg} daily for CrCl 50–79 mL/min\text{CrCl } 50\text{--}79\,\text{mL/min}, 1.5 mg1.5\,\text{mg} daily for CrCl 10–49 mL/min\text{CrCl } 10\text{--}49\,\text{mL/min}, and non-recommendation below CrCl 10 mL/min\text{CrCl } 10\,\text{mL/min}.

15
New cards

Risperidone renal adjustment

An antipsychotic regimen for severe renal impairment initiating at 0.5 mg0.5\,\text{mg} twice daily, allowing titration above 1.5 mg1.5\,\text{mg} twice daily only at intervals of at least one week.

16
New cards

Brexpiprazole renal limit

An SGA dosing cap specifying a maximum dose of 2 mg/day2\,\text{mg/day} in moderate-to-severe renal or hepatic impairment.

17
New cards

Memantine renal dosing

An NMDA receptor antagonist protocol for severe renal impairment establishing a target dose of 5 mg5\,\text{mg} twice daily for the immediate-release formulation or 14 mg14\,\text{mg} once daily for the extended-release formulation.

18
New cards

Galantamine renal thresholds

A cholinesterase inhibitor threshold limiting dosage to a maximum of 16 mg/day16\,\text{mg/day} for CrCl 9–59 mL/min\text{CrCl } 9\text{--}59\,\text{mL/min}, with an absolute contraindication to use if CrCl<9 mL/min\text{CrCl} < 9\,\text{mL/min}.

19
New cards

Glucuronidated Benzodiazepines (LOT)

Lorazepam, oxazepam, and temazepam; the safest benzodiazepines in renal disease because they are metabolized via glucuronidation into inactive metabolites and do not require renal dose adjustments.

20
New cards

Antidepressant Boxed Warning

An FDA boxed warning mandated on all antidepressant medications regarding increased risk of suicidal thoughts and behaviors in children, adolescents, and young adults under age 2525.

21
New cards

Shared SSRI Complications

Four adverse effects common across the SSRI class: hyponatremia/SIADH (most commonly emerging in the first 2–42\text{--}4 weeks), increased bleeding risk with NSAIDs and anticoagulants, sexual dysfunction, and discontinuation syndrome.

22
New cards

Citalopram QT prolongation

A dose-dependent cardiac conduction abnormality caused by citalopram, prompting a maximum dosing limit of 20 mg/day20\,\text{mg/day} in individuals over age 6060.

23
New cards

Paroxetine signature adverse profile

A distinctive side-effect spectrum comprising potent anticholinergic activity, weight gain, strong CYP2D6 enzyme inhibition, cardiac concerns in pregnancy, and the most severe discontinuation syndrome among SSRIs.

24
New cards

Bupropion seizure risk

A dose-dependent proconvulsant effect that makes bupropion strictly contraindicated in patients with active or historical seizure disorders and eating disorders.

25
New cards

Mirtazapine signature profile

Prominent sedation and weight gain caused by mirtazapine, which can be therapeutically beneficial when depression presents with concurrent insomnia and anorexia.

26
New cards

SNRI blood pressure elevation

A dose-dependent hypertensive complication characteristic of the SNRI class, requiring regular blood pressure monitoring during dose titration.

27
New cards

MAOI lethal complications

Severe reactions associated with monoamine oxidase inhibitors: hypertensive crisis triggered by tyramine-containing foods ('cheese reaction') and serotonin syndrome when co-administered with serotonergic agents.

28
New cards

MAOI washout periods

Mandatory drug clearance intervals before initiating an MAOI: wait 1414 days after stopping most antidepressants, and wait 55 weeks after stopping fluoxetine due to its long half-life.

29
New cards

Trazodone-induced priapism

A rare urologic emergency presenting as prolonged, painful penile erection that mandates immediate discontinuation of trazodone and emergent medical intervention.

30
New cards

Esketamine (Spravato) REMS

A specialized monitoring protocol requiring a 22-hour post-dose observation period for sedation and dissociation under a REMS program, accompanied by boxed warnings for sedation, dissociation, abuse, and suicidal ideation.

31
New cards

Zuranolone (Zurzuvae) boxed warning

An FDA boxed warning highlighting excessive sedation and severe impairment of driving ability.

32
New cards

Antipsychotic elderly dementia boxed warning

A class-wide FDA boxed warning for all antipsychotics denoting an approximately 1.6–1.7×1.6\text{--}1.7\times increase in mortality when used in elderly patients with dementia-related psychosis, alongside a separate warning for cerebrovascular adverse events (stroke/TIA).

33
New cards

SGA metabolic complications

A spectrum of metabolic disturbances including weight gain, diabetes mellitus, and dyslipidemia; highest in severity with olanzapine and clozapine, and lowest with aripiprazole, lurasidone, and cariprazine.

34
New cards

Acute dystonia

An acute extrapyramidal reaction characterized by involuntary, sustained muscle contractions that is treated with benztropine (1–2 mg1\text{--}2\,\text{mg}) or diphenhydramine (25–50 mg25\text{--}50\,\text{mg}, administered IM for severe cases).

35
New cards

Akathisia

A distressing extrapyramidal syndrome of subjective and motor restlessness, managed primarily by antipsychotic dose reduction or propranolol administration.

36
New cards

Pseudoparkinsonism

A medication-induced movement disorder presenting with rigidity, bradykinesia, and resting tremor, managed by reducing the antipsychotic dose or initiating amantadine.

37
New cards

Tardive dyskinesia

A delayed-onset, potentially irreversible movement disorder causing involuntary choreoathetoid movements, treated with VMAT2 inhibitors (valbenazine, deutetrabenazine).

38
New cards

Antipsychotic hyperprolactinemia

Endocrine dysfunction caused by dopamine receptor antagonism—most pronounced with risperidone and paliperidone—manifesting clinically as galactorrhea, gynecomastia, amenorrhea, and sexual dysfunction.

39
New cards

Antipsychotic orthostatic hypotension

Postural blood pressure drops mediated by alpha-1 adrenergic blockade, most prominently induced by quetiapine, iloperidone, and clozapine.

40
New cards

Aripiprazole signature adverse effects

Adverse reactions stemming from dopamine partial agonism, notably akathisia (inner restlessness) and impulse-control disorders (such as compulsive gambling and spending).

41
New cards

Clozapine boxed warnings

Five major FDA boxed warnings covering agranulocytosis, seizures, myocarditis, other adverse cardiovascular and respiratory effects, and increased mortality in elderly patients with dementia-related psychosis.

42
New cards

Clozapine gastrointestinal hypomotility

A potentially fatal anticholinergic GI complication producing severe constipation and paralytic ileus, requiring a routine prophylactic bowel regimen in older adults.

43
New cards

Clozapine REMS update (2025)

The official FDA removal of the shared Clozapine REMS program in 2025, which retained mandatory absolute neutrophil count (ANC) monitoring as specified by drug labeling.

44
New cards

Neuroleptic Malignant Syndrome (NMS)

A life-threatening neuropsychiatric emergency triggered by antipsychotics (or dopamine-antagonists) presenting with lead-pipe rigidity, hyperthermia, autonomic instability, elevated creatine kinase (CK), leukocytosis, and altered consciousness.

45
New cards

Lithium toxicity stages

A clinical progression of lithium poisoning advancing from mild gastrointestinal upset and fine tremor, to coarse tremor, ataxia, slurred speech, and confusion, culminating in seizures, dysrhythmias, and coma.

46
New cards

Lithium long-term organ complications

Chronic organ damage resulting from long-term lithium therapy, including nephrogenic diabetes insipidus, chronic kidney disease, hypothyroidism, hyperparathyroidism (requiring calcium monitoring), and weight gain.

47
New cards

Valproate boxed warnings

Three primary FDA boxed warnings denoting risks of severe hepatotoxicity, pancreatitis, and teratogenic fetal neural tube defects.

48
New cards

Valproate hyperammonemic encephalopathy

An episode of acute confusion and encephalopathy induced by valproate that can occur despite entirely normal liver transaminases, diagnosed by measuring serum ammonia.

49
New cards

Carbamazepine boxed warnings and screening

Boxed warnings for aplastic anemia, agranulocytosis, and serious cutaneous reactions (SJS/TEN), requiring mandatory HLA-B*15:02 genetic allele screening before initiation in patients of Asian ancestry.

50
New cards

Lamotrigine dermatologic warning

A boxed warning for life-threatening skin rashes (SJS/TEN) that necessitates immediate cessation of the drug upon any rash emergence, strict slow dosage titration, and dose adjustment when paired with valproate (which doubles lamotrigine serum levels).

51
New cards

Topiramate cognitive dulling ('dopamax')

A dose-limiting cognitive adverse effect characterized by psychomotor slowing, word-finding difficulty, and cognitive dulling that restricts its clinical utility in older adults.

52
New cards

Benzodiazepine boxed warnings

FDA boxed warnings emphasizing the high risk of abuse, misuse, and addiction, as well as profound sedation, respiratory depression, and death when co-administered with opioids.

53
New cards

Benzodiazepine withdrawal taper

A gradual discontinuation protocol reducing the daily dose by 5–10%5\text{--}10\% every 2–42\text{--}4 weeks to prevent life-threatening withdrawal seizures.

54
New cards

Complex sleep behaviors

A shared boxed warning for Z-drugs (zolpidem, eszopiclone, zaleplon) describing sleep-walking, sleep-driving, and other complex activities performed while not fully awake.

55
New cards

Stimulant boxed warning and monitoring

A boxed warning highlighting high potential for abuse and dependence, requiring clinical monitoring of blood pressure, heart rate, appetite, and pediatric growth.

56
New cards

Cholinesterase inhibitor cardiovascular risks

Parasympathetic vagal complications of Alzheimer's medications resulting in bradycardia, heart block, and syncope, which pose high risks in sick sinus syndrome or when co-prescribed with beta-blockers.

57
New cards

ChEI-anticholinergic drug interaction

A pharmacodynamically opposing drug combination wherein an anticholinergic agent worsens cognitive function and directly cancels the therapeutic receptor action of a cholinesterase inhibitor.

58
New cards

Serotonin syndrome

A toxic condition arising within 2424 hours of combining or escalating serotonergic drugs, characterized by neuromuscular hyperactivity (clonus, hyperreflexia), agitation, diaphoresis, and hyperthermia.

59
New cards

Serotonin syndrome treatment

Emergency management consisting of immediate discontinuation of serotonergic agents, external cooling, intravenous benzodiazepines for agitation, and cyproheptadine administration in moderate-to-severe cases.

60
New cards

Anticholinergic toxidrome

A toxic syndrome remembered by 'hot as a hare, blind as a bat, dry as a bone, red as a beet, mad as a hatter,' presenting with flushed dry skin, tachycardia, mydriasis, urinary retention, and delirium.

61
New cards

Clozapine myocarditis presentation

An early cardiac inflammatory complication manifesting as new-onset fever, tachycardia, chest pain, or dyspnea during the first few months of therapy, demanding urgent ECG and cardiac troponin evaluation.

62
New cards

Neuroleptic-induced dysphagia

An antipsychotic-mediated impairment of swallowing coordination in elderly patients that elevates aspiration pneumonia risk and necessitates meal monitoring and dose tapering.